{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:12:36Z","timestamp":1792782756063,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005971","name":"Deutsche Herzstiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institut f\u00fcr Herzinfarktforschung"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010578","name":"Deutsche Gesellschaft f\u00fcr Kardiologie-Herz und Kreislaufforschung.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arbeitsgemeinschaft Leitende Kardiologische Krankenhaus\u00e4rzte"},{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Maquet Cardiopulmonary AG"},{"name":"Teleflex Medical, Everett, MA, USA"},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this pooled sub-analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) and Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) trial was to compare the clinical outcome of patients with acute myocardial infarction complicated by cardiogenic shock treated either with clopidogrel or the newer, more potent ADP-receptor antagonists prasugrel or ticagrelor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      For the current analysis the primary endpoint was 1-year mortality and the secondary safety endpoint was moderate or severe bleedings until hospital discharge with respect to three different ADP-receptor antagonists. 856 patients were eligible for analysis. Of these, 507 patients (59.2%) received clopidogrel, 178 patients (20.8%) prasugrel and 171 patients (20.0%) ticagrelor as acute antiplatelet therapy. The adjusted rate of mortality after 1-year did not differ significantly between prasugrel and clopidogrel (hazard ratio [HR]: 0.81, 95% confidence interval [CI] 0.60\u20131.09, p\n                      <jats:sub>adj<\/jats:sub>\n                      \u2009=\u20090.17) or between ticagrelor and clopidogrel treated patients (HR: 0.86, 95% CI 0.65\u20131.15, p\n                      <jats:sub>adj<\/jats:sub>\n                      \u2009=\u20090.31). In-hospital bleeding events were significantly less frequent in patients treated with ticagrelor vs. clopidogrel (HR: 0.37, 95% CI 0.20 -0.69, p\n                      <jats:sub>adj<\/jats:sub>\n                      \u2009=\u20090.002) and not significantly different in patients treated with prasugrel vs. clopidogrel (HR: 0.73, 95% CI 0.43 -1.24, p\n                      <jats:sub>adj<\/jats:sub>\n                      \u2009=\u20090.24).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pooled sub-analysis is the largest analysis on safety and efficacy of three oral ADP-receptor antagonists and shows that acute therapy with either clopidogrel, prasugrel or ticagrelor is no independent predictor of 1-year mortality. Treatment with ticagrelor seems independently associated with less in-hospital moderate and severe bleeding events compared to clopidogrel. This finding might be due to selection bias and should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-021-01866-3","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:02:34Z","timestamp":1621209754000},"page":"1493-1503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9830-1941","authenticated-orcid":false,"given":"Martin","family":"Orban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kleeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Ouarrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Josef","family":"Feistritzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Fuernau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Noc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Neumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Desch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hausleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"5","key":"1866_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00392-017-1192-0","volume":"107","author":"T Backhaus","year":"2018","unstructured":"Backhaus T, Fach A, Schmucker J, Fiehn E, Garstka D (2018) Stehmeier J Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI Registry. Clin Res Cardiol 107(5):371\u2013379","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"1866_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/2048872617741735","volume":"7","author":"KS Rathod","year":"2017","unstructured":"Rathod KS, Koganti S, Iqbal MB, Jain AK, Kalra SS, Astroulakis Z (2017) Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. Eur Heart J Acute Cardiovasc Care 7(1):16\u201327","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"14","key":"1866_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","volume":"367","author":"H Thiele","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367(14):1287\u20131296","journal-title":"N Engl J Med"},{"issue":"3","key":"1866_CR4","first-page":"e00086","volume":"2020","author":"C Scherer","year":"2020","unstructured":"Scherer C, Kupka D, Stocker TJ, Joskowiak D, Scheuplein H, Sch\u00f6negger CM (2020) Isoflurane sedation in patients undergoing venoarterial extracorporeal membrane oxygenation treatment for cardiogenic shock-an observational propensity-matched study. Crit Care Explor March 2020(3):e00086","journal-title":"Crit Care Explor March"},{"issue":"2","key":"1866_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H (2017) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119\u2013177","journal-title":"Eur Heart J"},{"issue":"20","key":"1866_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015","journal-title":"N Engl J Med"},{"issue":"11","key":"1866_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057","journal-title":"N Engl J Med"},{"issue":"11","key":"1866_CR8","doi-asserted-by":"publisher","first-page":"e1395","DOI":"10.4244\/EIJY15M12_04","volume":"12","author":"M Orban","year":"2016","unstructured":"Orban M, Limbourg T, Neumann F-J, Ferenc M, Olbrich H-G, Richardt G (2016) ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis. EuroIntervention 12(11):e1395\u2013e1403","journal-title":"EuroIntervention"},{"issue":"12","key":"1866_CR9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1160\/th14-06-0489","volume":"112","author":"M Orban","year":"2014","unstructured":"Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S (2014) Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Thromb Haemost 112(12):1190\u20131197","journal-title":"Thromb Haemost"},{"issue":"25","key":"1866_CR10","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R (2017) PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 377(25):2419\u20132432","journal-title":"N Engl J Med"},{"issue":"16","key":"1866_CR11","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1161\/01.CIR.0000162477.70955.5F","volume":"111","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Morrow DA, Giugliano RP, Burton Paul BJ, Murphy SA, McCabe CH (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111(16):2042\u20132049","journal-title":"Circulation"},{"issue":"16","key":"1866_CR12","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J (2019) Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med 381(16):1524\u20131534","journal-title":"N Engl J Med"},{"issue":"10","key":"1866_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.118.036614","volume":"139","author":"S Benedikt","year":"2019","unstructured":"Benedikt S, Karim I, Tobias L, Nikos W, Jan-Malte S, Federico P (2019) Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 139(10):1249\u20131258","journal-title":"Circulation"},{"key":"1866_CR14","doi-asserted-by":"crossref","unstructured":"Freund Anne, Jobs Alexander, Lurz Philipp, Feistritzer Hans-Josef, de Waha-Thiele Suzanne, Meyer-Saraei Roza (2020) Frequency and impact of bleeding on outcome in patients with cardiogenic shock. JACC Cardiovasc Interv 13(10):1182\u20131193","DOI":"10.1016\/j.jcin.2020.02.042"},{"issue":"12","key":"1866_CR15","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3390\/jcm9123803","volume":"9","author":"C Scherer","year":"2020","unstructured":"Scherer C, L\u00fcsebrink E, Kupka D, Stocker TJ, Stark K, Stremmel C (2020) Long-term clinical outcome of cardiogenic shock patients undergoing impella cp treatment vs standard of care. J Clin Med 9(12):3803","journal-title":"J Clin Med"},{"issue":"2","key":"1866_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40119-018-0118-x","volume":"7","author":"A Elbadawi","year":"2018","unstructured":"Elbadawi A, Elgendy IY, Mohamed AH, Barssoum K, Alotaki E, Ogunbayo GO (2018) Clopidogrel Versus Newer P2Y12 antagonists for percutaneous coronary intervention in patients with out-of-hospital cardiac arrest managed with therapeutic hypothermia: a meta-analysis. Cardiol Ther 7(2):185\u2013189","journal-title":"Cardiol Ther"},{"issue":"3","key":"1866_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","volume":"5","author":"P Grimfj\u00e4rd","year":"2019","unstructured":"Grimfj\u00e4rd P, Lagerqvist B, Erlinge D, Varenhorst C, James S (2019) Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother 5(3):151\u2013157","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"1866_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.thromres.2015.04.029","volume":"136","author":"M Orban","year":"2015","unstructured":"Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S (2015) The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. Thromb Res 136(1):87\u201393","journal-title":"Thromb Res"},{"issue":"10104","key":"1866_CR19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. The Lancet 390(10104):1747\u20131757","journal-title":"The Lancet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01866-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T07:05:02Z","timestamp":1630307102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01866-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01866-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"23 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin Orban has received (directly or indirectly) speaker honoraria from Abbott Medical, AstraZeneca, Abiomed, Bayer vital, BIOTRONIK, Bristol-Myers Squibb, CytoSorbents, Daiichi Sankyo Deutschland, Edwards Lifesciences Services, Sedana Medical, outside the submitted work. J\u00f6rg Hausleiter received speaker honoraria and research support from Abbott Vascular and Edwards Lifesciences, outside the submitted work. Kurt Huber received lecture fees from AstraZeneca, Daiichi Sankyo and Sanofi Aventis, outside the submitted work. Peter Clemmensen has previously or currently been involved in research contracts, consulting, speakers bureau or received research and educational grants from: Abbott, Acarix, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli-Lilly, Evolva, Fibrex, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Regado, Sanofi, Searle, Servier, Quantum. Tobias Geisler reports speaker honoraria from Astra Zeneca, Boehringer Ingelheim, Ferrer, and Pfizer; grants and honoraria from BayerHealthcare, BristolMyers Squibb, Daiichi Sankyo, Medtronic and Edwards Lifesciences and is supported by the German Research Foundation (DFG) \u2013 Project number 374031971 \u2013 TRR 240. The other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was performed according to the Declaration of Helsinki for Human Research and approved by the respective local ethics committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors consent to publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}